Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Temozolomide | |
| Synonyms |
|
|
| Definitions |
A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1244 |
|
| Accepted_Therapeutic_Use_For |
Malignant glioma (Anaplastic astrocytoma; Anaplastic oligodendrogliomas; Anaplastic oligoastrocytomas; Glioblastoma multiforme); Metastatic melanoma
|
|
| ALT_DEFINITION |
A drug that is used to treat certain types of brain tumors in adults and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents.
|
|
| CAS_Registry |
85622-93-1
|
|
| Chemical_Formula |
C6H6N6O2
|
|
| code |
C1244
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)
|
|
| Display_Name |
Temozolomide
|
|
| FDA_UNII_Code |
YF1K15M17Y
|
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Temozolomide
|
|
| Legacy Concept Name |
Temozolomide
|
|
| Maps_To |
Temozolomide
|
|
| NCI_Drug_Dictionary_ID |
41671
|
|
| NSC Number |
362856
|
|
| PDQ_Closed_Trial_Search_ID |
41671
|
|
| PDQ_Open_Trial_Search_ID |
41671
|
|
| Preferred_Name |
Temozolomide
|
|
| prefixIRI |
NCIT:C1244
|
|
| prefLabel |
Temozolomide
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C0076080
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |